[go: up one dir, main page]

WO1992005266A3 - Cellules d'encapsidation - Google Patents

Cellules d'encapsidation Download PDF

Info

Publication number
WO1992005266A3
WO1992005266A3 PCT/US1991/006852 US9106852W WO9205266A3 WO 1992005266 A3 WO1992005266 A3 WO 1992005266A3 US 9106852 W US9106852 W US 9106852W WO 9205266 A3 WO9205266 A3 WO 9205266A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
retrovirus
recombinant
particular cell
cell type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/006852
Other languages
English (en)
Other versions
WO1992005266A2 (fr
Inventor
Douglas J Jolly
Jack R Barber
James G Respess
Stephen M W Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Viagene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Viagene Inc filed Critical Chiron Viagene Inc
Priority to CA002092195A priority Critical patent/CA2092195C/fr
Priority to AU88424/91A priority patent/AU665176B2/en
Publication of WO1992005266A2 publication Critical patent/WO1992005266A2/fr
Publication of WO1992005266A3 publication Critical patent/WO1992005266A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/30—Rearing or breeding invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13051—Methods of production or purification of viral material
    • C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention permet la production de rétrovirus recombinés (particules vectorielles rétrovirales) à partir de cellules productrices plus sûres et d'un titre supérieur à la normale. De plus, l'invention concerne des procédés de production de cellules auxiliaires qui, lorsqu'un génome de rétrovirus recombiné est introduit afin de produire une lignée productrice, produisent des particules dont les cibles sont des types particuliers de cellules. De plus, l'invention concerne des procédés de production de systèmes de rétrovirus recombinés adaptés pour infecter un type particulier de cellules, tel qu'une tumeur, par liaison du rétrovirus ou du rétrovirus recombiné dans le type particulier de cellules. En outre, l'invention concerne des procédés de production de rétrovirus recombinés s'intégrant dans un petit nombre spécifique d'endroits dans le génome hôte, et des procédés de production de rétrovirus recombinés à partir d'animaux transgéniques.
PCT/US1991/006852 1990-09-21 1991-09-20 Cellules d'encapsidation Ceased WO1992005266A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002092195A CA2092195C (fr) 1990-09-21 1991-09-20 Lignee cellulaire a encapsidation retrovirale
AU88424/91A AU665176B2 (en) 1990-09-21 1991-09-20 Packaging cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58660390A 1990-09-21 1990-09-21
US586,603 1990-09-21

Publications (2)

Publication Number Publication Date
WO1992005266A2 WO1992005266A2 (fr) 1992-04-02
WO1992005266A3 true WO1992005266A3 (fr) 1992-07-23

Family

ID=24346413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/006852 Ceased WO1992005266A2 (fr) 1990-09-21 1991-09-20 Cellules d'encapsidation

Country Status (5)

Country Link
EP (3) EP1285967A3 (fr)
JP (3) JPH06500923A (fr)
AU (2) AU665176B2 (fr)
CA (1) CA2092195C (fr)
WO (1) WO1992005266A2 (fr)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662896A (en) * 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6027722A (en) * 1990-10-25 2000-02-22 Nature Technology Corporation Vectors for gene transfer
US5512421A (en) * 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
WO1993020221A1 (fr) * 1992-04-03 1993-10-14 Young Alexander T Therapie genique utilisant des vecteurs viraux cibles
AU4259193A (en) * 1992-04-28 1993-11-29 Frank Andreas Harald Meyer Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament
ATE245703T1 (de) 1992-09-22 2003-08-15 Biofocus Discovery Ltd Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren
WO1994011524A1 (fr) * 1992-11-09 1994-05-26 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Particules vectorielles pouvant etre ciblees
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
WO1994019478A1 (fr) * 1993-02-22 1994-09-01 The Rockefeller University Production de retrovirus exempts d'auxiliaires, a titre eleve par transfection transitoire
EP0688358A4 (fr) 1993-03-12 1997-10-01 Univ Creighton Vecteurs ameliores en therapie genique
FR2707091B1 (fr) 1993-06-30 1997-04-04 Cohen Haguenauer Odile Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes.
FR2716461A1 (fr) * 1994-02-22 1995-08-25 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ（ユーケー）リミテッド 非交差性レトロウイルスベクター
US6013517A (en) 1994-05-09 2000-01-11 Chiron Corporation Crossless retroviral vectors
AU2648295A (en) * 1994-06-07 1996-01-04 Immunomedics Inc. Safe retroviral vectors, their production and use
US5952225A (en) * 1994-08-17 1999-09-14 Genetic Therapy, Inc. Retroviral vectors produced by producer cell lines resistant to lysis by human serum
US5698446A (en) * 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
WO1996012809A2 (fr) 1994-10-20 1996-05-02 Institut Pasteur Sequences nucleotidiques d'antigenes retroviraux vih-1 groupe (ou sous-groupe) o
FR2727429B1 (fr) * 1994-11-30 1997-11-28 Haguenauer Odile Cohen Lignees d'encapsidation et vecteurs d'expression pour la transcomplementation de vecteurs retroviraux defectifs
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
JP2001509661A (ja) 1996-01-23 2001-07-24 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ トランス支配性細胞内作用因子ペプチドおよびｒｎａ分子のスクリーニング方法
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6723531B2 (en) 1996-04-05 2004-04-20 The Salk Institute For Biological Studies Method for modulating expression of exogenous genes in mammalian systems, and products related thereto
WO1997042338A1 (fr) * 1996-05-06 1997-11-13 Chiron Corporation Vecteurs retroviraux sans croisement
US5928638A (en) * 1996-06-17 1999-07-27 Systemix, Inc. Methods for gene transfer
US5739018A (en) * 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6133027A (en) * 1996-08-07 2000-10-17 City Of Hope Inducible expression system
WO1998012332A1 (fr) 1996-09-17 1998-03-26 Chiron Corporation Compositions et procedes de traitement de maladies intracellulaires
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6300488B1 (en) 1997-07-10 2001-10-09 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in transcription and regulation of transgene expression
ATE376062T1 (de) 1997-08-04 2007-11-15 Cell Genesys Inc Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
EP1900818A3 (fr) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Antigènes de Neisserial
EP2210945B1 (fr) 1998-01-14 2013-06-26 Novartis Vaccines and Diagnostics S.r.l. Antigènes de Neisseria meningitidis
EP2261355A3 (fr) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Antigènes de Neisseria meningitidis et compositions
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
EP1121437B1 (fr) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Genes regules dans les cellules du cancer du sein metastatique et du cancer du colon
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
EP1141331B1 (fr) 1998-12-16 2008-09-17 Novartis Vaccines and Diagnostics, Inc. KINASE DEPENDANT DE LA CYCLINE DE TYPE HUMAIN (hPNQALRE)
WO2000055343A2 (fr) * 1999-03-15 2000-09-21 Chiron Corporation Procedes de production d'une lignee cellulaire produisant un vecteur utilisant une pluralite de transductions
AU4309600A (en) 1999-04-30 2000-11-17 Chiron S.R.L. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US7504253B2 (en) 1999-06-11 2009-03-17 The Burnham Institute For Medical Research Nucleic acid encoding proteins involved in protein degradation, products and methods related thereof
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
PT2275552E (pt) 1999-10-29 2015-12-07 Glaxosmithkline Biolog Sa Péptidos antigénicos de neisseria
WO2001036640A2 (fr) 1999-11-18 2001-05-25 Chiron Corporation Gene humain fgf-21 et produits d'expression genique
CA2397508C (fr) 2000-01-17 2015-11-24 Chiron Spa Vaccin a base de vesicule de membrane externe (omv) comprenant des proteines de membrane externe du serogroupe b de n. meningitis
PT1790660E (pt) 2000-02-28 2012-09-17 Novartis Vaccines & Diagnostic Expressão heteróloga de proteínas de neisseria
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
CN102151337B (zh) 2000-03-13 2014-03-12 恩根尼公司 调节消化道蛋白表达的组合物和方法
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
GB0024550D0 (fr) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
WO2002034771A2 (fr) 2000-10-27 2002-05-02 Chiron Srl Acides nucleiques et proteines derives des groupes de streptocoques a et b
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2002081641A2 (fr) 2001-04-06 2002-10-17 Georgetown University Gene scc-112 et utilisations diagnostique et therapeutique de ce gene
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002303261A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
CA2344208A1 (fr) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Methode
RU2331435C2 (ru) 2001-12-12 2008-08-20 Чирон Срл. Иммунизация против chlamydia trachomatis
EP2348119B1 (fr) 2002-02-01 2017-04-26 Oxford BioMedica (UK) Limited Vecteur de lentivirus multicistronique
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
US20070059329A1 (en) 2002-11-15 2007-03-15 Nathalie Norais Unexpected surface proteins in meningococcus
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
WO2006007539A1 (fr) * 2004-07-01 2006-01-19 Virxsys Corporation Lignee cellulaire d'encapsidation de vecteurs
CA2524619A1 (fr) 2005-11-22 2007-05-22 Ottawa Health Research Institute Nouvelles cellules souches, sequences nucleotides et proteines provenant de celles-ci
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
EP2054431B1 (fr) 2006-06-09 2011-08-31 Novartis AG Conformères d'adhésines bactériennes
WO2008152446A2 (fr) 2006-11-27 2008-12-18 Patrys Limited Nouvelle cible de peptide glycosylé dans des cellules néoplasiques
MX2009008413A (es) 2007-02-06 2009-11-02 Tai June Yoo Tratamiento y prevencion de enfermedades neurodegenerativas usando terapia genica.
US8673859B2 (en) 2007-03-20 2014-03-18 New York University GM-CSF cosmeceutical compositions and methods of use thereof
WO2009058451A2 (fr) 2007-08-02 2009-05-07 California Stem Cell, Inc. Cellules progénitrices neuronales et procédés de dérivation et de purification de cellules progénitrices neuronales de cellules souches embryonnaires
EP2215269B1 (fr) 2007-10-15 2017-12-13 Admedus Vaccines Pty Limited Système de construction et utilisations pour celui-ci
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
US8324182B2 (en) 2008-02-15 2012-12-04 Tufts University Humanized model of membrane attack complex (MAC) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
US8999919B2 (en) 2008-10-22 2015-04-07 Trustees Of Dartmouth College Compositions and methods for inhibiting the interaction between CFTR and CAL
US8211487B2 (en) 2008-11-26 2012-07-03 Srinivasan Damodaran Inhibition of ice crystal growth
EP2417984B1 (fr) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Procédé pour le traitement d'une tumeur sanguine utilisant un anticorps anti-tim-3
US8492119B2 (en) 2009-04-27 2013-07-23 Kyowa Hakko Kirin Co., Ltd Antibody to human IL-3 receptor alpha chain
WO2010148203A2 (fr) * 2009-06-17 2010-12-23 Tocagen Inc. Cellules productrices pour vecteurs rétroviraux compétents en réplication
US9556272B2 (en) 2009-11-11 2017-01-31 The Trustees Of The University Of Pennsylvania Anti-TEM1 antibodies and uses thereof
GB0920775D0 (en) 2009-11-26 2010-01-13 King S College Cells
US9795658B2 (en) 2010-04-20 2017-10-24 Admedus Vaccines Pty Ltd Expression system for modulating an immune response
CA2843684A1 (fr) 2010-08-13 2012-02-16 Tufts University Compositions, trousses et methodes de traitement de la degenerescence maculaire au moyen de la proteine cd59 soluble independante de la membrane
EP2698635A3 (fr) 2010-12-01 2014-05-28 The University Of North Carolina At Chapel Hill Procédés et compositions pour cibler des sites de croissance néovasculaire
CA2848765A1 (fr) 2011-09-15 2013-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Immunotherapie et diagnostic de la mucormycose au moyen de coth
US9783610B2 (en) 2012-04-27 2017-10-10 The Trustees Of The University Of Pennsylvania Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
JP2016514091A (ja) 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
WO2014197586A1 (fr) 2013-06-04 2014-12-11 Virginia Commonwealth University Promoteur du gène de la synténine (mda-9) utilisé pour la prise d'image et le traitement de cellules cancéreuses métastatiques
WO2014197599A1 (fr) 2013-06-04 2014-12-11 The Johns Hopkins University Expression en surface de l'avidine/streptavidine, médiée par peg-prom
EP3003393A4 (fr) 2013-06-04 2017-01-11 The Johns Hopkins University Produits de recombinaison d'acides nucléiques tripartites utilisables dans le cadre de la théranostique du cancer
WO2014197535A1 (fr) 2013-06-04 2014-12-11 Virginia Commonwealth University Cytokines thérapeutiques recombinantes contre le cancer
EP3003022B1 (fr) 2013-06-04 2017-11-22 Virginia Commonwealth University Utilisation d'un promoteur de ccn1 tronqué pour le diagnostic, la thérapeutique et la théragnostique de cancer
US20160152952A1 (en) 2013-06-25 2016-06-02 Temple University-Of The Commonwealth System Of Higher Education Cortical Bone-Derived Stem Cells
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
EP3122884B1 (fr) 2014-03-26 2019-12-25 Tocagen Inc. Vecteur rétroviral à activité de stimulation immunitaire
EP3186269B1 (fr) 2014-08-28 2021-03-10 Tufts University Compositions, procédés et kits pour le traitement des troubles liés au complément
GB201415344D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Protein
US9901639B2 (en) 2015-02-13 2018-02-27 Temple University—Of the Commonwealth System of Higher Education Bone marrow origin progenitor cell or endothelial progenitor cell in combination with DNMT1 gene therapy for vascular repair in metabolic disease
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CA3006779A1 (fr) 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Composition immunomodulatrice pour le traitement
GB201603372D0 (en) * 2016-02-26 2016-04-13 Ucl Business Plc Cell
AU2017250191A1 (en) 2016-04-13 2018-11-08 Orimabs Ltd. Anti-PSMA antibodies and use thereof
EP3299460A1 (fr) 2016-09-26 2018-03-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Nouveaux composes et procedes destines a moduler l'expression de l'ubiquitination
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
EP4442320A3 (fr) 2018-02-12 2024-12-25 Trustees Of Tufts College Procédés d'inhibition de l'activation d'inflammasome
EP3781130A4 (fr) 2018-04-11 2022-01-26 Precision Molecular Inc. Combinaisons thérapeutiques pour le traitement du cancer
MX2021007539A (es) 2018-12-21 2021-09-21 Univ Griffith Composiciones, metodos y usos para provocar una respuesta inmune.
US12098212B2 (en) 2019-08-12 2024-09-24 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
WO2021074695A1 (fr) 2019-10-16 2021-04-22 Avacta Life Sciences Limited FRACTIONS DE MÉDICAMENTS BISPÉCIFIQUES DE L'INHIBITEUR DE PD-L1 ET DE L'INHIBITEUR DE TGFβ
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
WO2022234003A1 (fr) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Polypeptides se liant à cd33 avec protéine stefin a
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
WO2023057946A1 (fr) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Polypeptides sériques de liaison pd-l1 prolongés à demi-vie
US20250018063A1 (en) 2021-11-19 2025-01-16 Janssen Biotech, Inc. Method of Treating Geographic Atrophy with a Gene Therapy Vector Expressing Soluble CD59
US20250289903A1 (en) 2022-04-29 2025-09-18 Purinnomia Biotech, Inc. Methods and compositions for treating eosinophil driven diseases and disorders
WO2025074268A1 (fr) 2023-10-02 2025-04-10 Janssen Biotech, Inc. Méthodes pour traiter la dégénérescence maculaire

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008454A1 (fr) * 1987-04-23 1988-11-03 State Of Oregon Acting By And Through The State Bo Procede permettant d'amplifier l'expression et la transmission de genes clones dans des cellules eucaryotiques
EP0386882A1 (fr) * 1989-02-06 1990-09-12 Dana Farber Cancer Institute Provirus d'HIV défectif pour l'empaquetage, lignées cellulaires et leur utilisation
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03504079A (ja) * 1988-03-21 1991-09-12 カイロン　コーポレイション 組換えレトロウィルス
WO1991019803A1 (fr) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Particules virales autoassemblees defectueuses qui ne se propagent pas d'elles-memes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988008454A1 (fr) * 1987-04-23 1988-11-03 State Of Oregon Acting By And Through The State Bo Procede permettant d'amplifier l'expression et la transmission de genes clones dans des cellules eucaryotiques
EP0386882A1 (fr) * 1989-02-06 1990-09-12 Dana Farber Cancer Institute Provirus d'HIV défectif pour l'empaquetage, lignées cellulaires et leur utilisation
WO1991002805A2 (fr) * 1989-08-18 1991-03-07 Viagene, Inc. Retrovirus de recombinaison apportant des constructions de vecteur a des cellules cibles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Virology, vol. 64, no. 3, March 1990, F.-L. COSSET et al.: "A new avian leukosis virus-based packaging cell line that uses two separate transcomplementing helper genomes", pages 1070-1078, see the whole document, specially page 1076, column 2 *
Nucleic Acids Research, vol. 18, no. 12, 25 June 1990, J.P. MORGENSTERN et al.: "Advanced mammalian gene tranfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line", pages 3587-3596, see the whole document *

Also Published As

Publication number Publication date
AU4798496A (en) 1996-06-20
JP4092278B2 (ja) 2008-05-28
AU8842491A (en) 1992-04-15
AU690427B2 (en) 1998-04-23
EP1285967A3 (fr) 2005-03-02
AU665176B2 (en) 1995-12-21
EP1285967A2 (fr) 2003-02-26
EP0854193A1 (fr) 1998-07-22
JP2004041234A (ja) 2004-02-12
CA2092195C (fr) 2000-04-18
CA2092195A1 (fr) 1992-03-22
JPH06500923A (ja) 1994-01-27
EP0549723A1 (fr) 1993-07-07
WO1992005266A2 (fr) 1992-04-02
JP2003159062A (ja) 2003-06-03

Similar Documents

Publication Publication Date Title
WO1992005266A3 (fr) Cellules d'encapsidation
GB2325003A (en) Rectroviral vectors
CA2328404A1 (fr) Nouvelles cellules lentivirales d'encapsidation
DE60028066D1 (de) Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen
CA2074355A1 (fr) Plants de mais transgeniques fertiles
BG103334A (en) Antiviral vectors
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
WO1996037623B1 (fr) Vecteurs retroviraux
WO2000017365A8 (fr) Systeme binaire d'expression virale dans des plantes
CA2130454A1 (fr) Production de plantes viro-resistantes par l'introduction d'arn viral sens non traduisible
HUP9801855A2 (hu) Növényekben szintetizált és azokból kinyert módosított keményítő, valamint eljárás előállításukra
NO163620C (no) Ethylenpolymerer inneholdende enheter avledet fra maleinsyreanhydrid, fremgangsmaate for fremstilling av pylymerene og deres anvendelse for fremstilling av folier.
NO975813D0 (no) Innkapslede celler som produserer virale partikler
HU9200260D0 (en) Plazmide-producing process for producing posttransformed retrovirus gene, plazmide from them and products from them
WO1996007749A3 (fr) Procedes et compositions d'inhibition de la production de virus aptes a la replication
JPH10507628A (ja) 非自己不活化性の発現標的化レトロウイルスベクタ
CA2329510A1 (fr) Sequences de type promoteur exprimees dans les antheres et les pollens
WO1999020742A3 (fr) Lignee cellulaire d'encapsidation produisant un mlv pseudo-type ar siv
DK0817860T3 (da) Pseudotype retrovirale partikler
RU2006123079A (ru) Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы
AU7514087A (en) Vaccine containing the protein f of the aids virus
EP0101288A3 (fr) Aryl(aryloxy- ou arylthio)azolométhanes, leurs préparation et utilisation
CA2331440A1 (fr) Lignee cellulaire d'encapsidation de retrovirus amphotropique, procede de production et d'utilisation de ladite lignee
CA2004646A1 (fr) Protease, transcriptase inverse et endonucleases de retrovirus, et methode de production de ces enzymes
NZ196835A (en) Total synthesis of irs 4sr 5rs-4-(4,8-dimethyl-5-hydroxy-7-nonenyl)-4-methyl-3,8-dioxabicyclo-(3.2.1)octane-1-acetic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MC MG MN MW NO PL RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/10-10/10,DRAWINGS,REPLACED BY NEW PAGES 1/10-10-10;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA CS FI HU JP KP KR LK MC MG MN MW NO PL RO SD SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2092195

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991919095

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991919095

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991919095

Country of ref document: EP